Ron Bentsur is CEO & Chairman at Nuvectis Pharma, Inc. (NVCT). They have made 82 open-market trades across 5 companies since 2006, most recently 2026-06-30.
CIK 0001251213
55 open-market purchases totalling $3.5M since 2006, against 27 sales. Across 53 scored buys the stock is up 7.3% at ninety days, and 6.8 points ahead of the S&P over the same stretch.
53 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 32% | 36% | 32% |
| Avg Move | -5.4% | -2.8% | +7.3% |
| Alpha | -5.1% | -2.0% | +6.8% |
| Scored | 53 | 53 | 53 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCT | BUY | 2026-06-30 | 2026-07-01 | $20.00 | $250K | -6.4% | +9.8% | +5.3% |
| NVCT | BUY | 2025-11-05 | 2025-11-06 | $5.72 | $29K | +6.5% | +17.1% | +48.9% |
| NVCT | BUY | 2024-12-24 | 2024-12-26 | $4.65 | $21K | +26.4% | +37.9% | +79.3% |
| NVCT | BUY | 2024-11-15 | 2024-11-18 | $4.92 | $98K | +0.8% | -6.0% | +54.8% |
| NVCT | BUY | 2024-05-14 | 2024-05-15 | $6.74 | $13K | -0.3% | +2.6% | -2.1% |
| NVCT | BUY | 2024-05-10 | 2024-05-13 | $6.40 | $13K | +5.0% | +4.6% | -0.9% |
| NVCT | BUY | 2024-03-18 | 2024-03-19 | $10.29 | $103K | -12.0% | -25.4% | -24.0% |
| NVCT | BUY | 2023-10-10 | 2023-10-12 | $11.08 | $7K | -10.5% | -17.2% | -2.2% |
| NVCT | BUY | 2023-10-06 | 2023-10-10 | $11.21 | $12K | -13.1% | -22.1% | -4.1% |
| NVCT | BUY | 2023-10-04 | 2023-10-06 | $11.01 | $35K | -14.9% | -16.2% | -24.0% |
| NVCT | BUY | 2023-08-15 | 2023-08-16 | $14.61 | $5K | -8.6% | -2.8% | -43.8% |
| NVCT | BUY | 2023-08-08 | 2023-08-11 | $14.73 | $4K | -3.9% | -8.7% | -45.2% |
| NVCT | BUY | 2023-07-20 | 2023-07-24 | $14.92 | $5K | -0.3% | -0.7% | -38.1% |
| NVCT | BUY | 2023-07-19 | 2023-07-20 | $14.33 | $3K | -3.8% | +4.2% | -34.5% |
| NVCT | BUY | 2023-07-07 | 2023-07-18 | $15.52 | $4K | -6.7% | -2.2% | -27.7% |
| NVCT | BUY | 2023-07-06 | 2023-07-07 | $14.88 | $5K | -5.8% | -5.3% | -29.4% |
| NVCT | BUY | 2023-06-26 | 2023-06-27 | $16.50 | $12K | -3.3% | -15.7% | -17.8% |
| NVCT | BUY | 2023-06-21 | 2023-06-22 | $17.88 | $9K | -11.7% | -18.7% | -23.6% |
| NVCT | BUY | 2023-06-07 | 2023-06-08 | $17.45 | $6K | +0.9% | -8.2% | -19.7% |
| NVCT | BUY | 2023-05-31 | 2023-06-01 | $17.28 | $6K | +4.5% | -7.5% | -16.9% |
| NVCT | BUY | 2023-05-24 | 2023-05-26 | $17.49 | $3K | -0.1% | -6.3% | -17.5% |
| NVCT | BUY | 2023-05-16 | 2023-05-18 | $17.03 | $5K | +2.9% | +5.9% | -16.1% |
| NVCT | BUY | 2023-03-23 | 2023-03-27 | $12.13 | $3K | +9.4% | +24.9% | +38.5% |
| NVCT | BUY | 2023-03-21 | 2023-03-23 | $12.08 | $6K | +13.5% | +21.5% | +50.3% |
| XAIR | BUY | 2023-03-20 | 2023-03-21 | $6.48 | $15K | -0.9% | -16.6% | -9.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.